Business
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be addedENGLEWOOD, CO / ACCESSWIRE / September 9, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the formation of its Scientific Advisory Board, chaired by Dr. Hal Dietz, Professor of Genetic Medicine at the Johns Hopkins University School of Medicine. Other initial members of the SAB include Dr. Xavier Jeunemaitre, Professor of Genetics at University Paris Descartes, Dr. Shaine Morris, Medical Director of Cardiovascular Genetics at Texas Children's Hospital and Associate Professor at Baylor College of Medicine, Dr. Bart Loeys, Professor at the Center for Medical Genetics of the Antwerp University Hospital and Radboud University Medical Center in Nijmegen, and Dr. Peter Byers, Professor in the Department of Laboratory Medicine and Pathology and Department of Medicine (Medical Genetics) at the University of Washington. These prominent physicians will advise Aytu BioPharma to advance the global development of AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. There are currently no U.S. Food and Drug Administration (FDA)-approved treatments for VEDS.\"We are honored to have our chair, Dr. Hal Dietz, as well as our key advisors Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers join this newly formed SAB. Their collective expertise will prove invaluable as we progress toward a single pivotal study of AR101 in VEDS and seek strategies to minimize the clinical risk associated with the trial and hopefully advance this novel potential treatment option so that we can positively impact patients diagnosed with this devastating disease,\" commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. \"We look forward to adding additional key opinion leaders to the SAB to lend their expertise to the development of AR101 in VEDS.\"Hal Dietz, M.D. - Chairman of the Scie...